Tatiana Georgiesh1,2, Ninna Aggerholm-Pedersen3, Patrick Schöffski4, Yifan Zhang5, Andrea Napolitano6, Judith V M G Bovée7, Åse Hjelle8, Gordon Tang9, Mateusz Spalek10, Margherita Nannini11, David Swanson12, Thomas Baad-Hansen13, Raf Sciot14, Asle C Hesla15, Paul Huang16, Desiree Dorleijn17, Hans Kristian Haugland18, Maribel Lacambra19, Jacek Skoczylas10, Maria A Pantaleo20, Rick L Haas21, Leonardo A Meza-Zepeda2,22, Florian Haller23, Anna M Czarnecka10, Herbert Loong19, Nina L Jebsen8, Michiel van de Sande17, Robin L Jones6, Felix Haglund5, Iris Timmermans4, Akmal Safwat3, Bodil Bjerkehagen1,24, Kjetil Boye25,26. 1. Department of Pathology, Oslo University Hospital, Oslo, Norway. 2. Department of Tumour Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 3. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. 5. Department of Oncology-Pathology, Karolinska Institutet and Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. 6. Sarcoma Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. 7. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. 8. Department of Oncology, Haukeland University Hospital, Bergen, Norway. 9. Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong SAR, China. 10. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 11. Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 12. Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. 13. Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark. 14. Department of Pathology, University Hospitals Leuven, Leuven, Belgium. 15. Department of Molecular Medicine and Surgery, Karolinska Institutet and Clinical Orthopaedics, Karolinska University Hospital, Stockholm, Sweden. 16. Division of Molecular Pathology, The Institute of Cancer Research, London, UK. 17. Department of Orthopedic Surgery, Bone and Soft Tissue Tumor Unit, Leiden University Medical Center, Leiden, The Netherlands. 18. Department of Pathology, Haukeland University Hospital, Bergen, Norway. 19. Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China. 20. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. 21. Department of Radiotherapy, the Netherlands Cancer Institute, Amsterdam, The Netherlands and Department of Radiotherapy, the Leiden University Medical Center, Leiden, The Netherlands. 22. Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 23. Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. 24. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 25. Department of Tumour Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. kjetil.boye@rr-research.no. 26. Department of Oncology, Oslo University Hospital, Oslo, Norway. kjetil.boye@rr-research.no.
Abstract
BACKGROUND: Current risk models in solitary fibrous tumour (SFT) were developed using cohorts with short follow-up and cannot reliably identify low-risk patients. We recently developed a novel risk model (G-score) to account for both early and late recurrences. Here, we aimed to validate the G-score in a large international cohort with long-term follow-up. METHODS: Data were collected from nine sarcoma referral centres worldwide. Recurrence-free interval (RFi) was the primary endpoint. RESULTS: The cohort comprised 318 patients with localised extrameningeal SFTs. Disease recurrence occurred in 96 patients (33%). The estimated 5-year RFi rate was 72%, and the 10-year RFi rate was 52%. G-score precisely predicted recurrence risk with estimated 10-year RFi rate of 84% in low risk, 54% in intermediate risk and 36% in high risk (p < 0.001; C-index 0.691). The mDemicco (p < 0.001; C-index 0.749) and SalasOS (p < 0.001; C-index 0.674) models also predicted RFi but identified low-risk patients less accurate with 10-year RFi rates of 72% and 70%, respectively. CONCLUSIONS: G-score is a highly significant predictor of early and late recurrence in SFT and is superior to other models to predict patients at low risk of relapse. A less intensive follow-up schedule could be considered for patients at low recurrence risk according to G-score.
BACKGROUND: Current risk models in solitary fibrous tumour (SFT) were developed using cohorts with short follow-up and cannot reliably identify low-risk patients. We recently developed a novel risk model (G-score) to account for both early and late recurrences. Here, we aimed to validate the G-score in a large international cohort with long-term follow-up. METHODS: Data were collected from nine sarcoma referral centres worldwide. Recurrence-free interval (RFi) was the primary endpoint. RESULTS: The cohort comprised 318 patients with localised extrameningeal SFTs. Disease recurrence occurred in 96 patients (33%). The estimated 5-year RFi rate was 72%, and the 10-year RFi rate was 52%. G-score precisely predicted recurrence risk with estimated 10-year RFi rate of 84% in low risk, 54% in intermediate risk and 36% in high risk (p < 0.001; C-index 0.691). The mDemicco (p < 0.001; C-index 0.749) and SalasOS (p < 0.001; C-index 0.674) models also predicted RFi but identified low-risk patients less accurate with 10-year RFi rates of 72% and 70%, respectively. CONCLUSIONS: G-score is a highly significant predictor of early and late recurrence in SFT and is superior to other models to predict patients at low risk of relapse. A less intensive follow-up schedule could be considered for patients at low recurrence risk according to G-score.
Authors: Winan J van Houdt; Charlotte M A Westerveld; Joyce E P Vrijenhoek; Joost van Gorp; Frits van Coevorden; Cornelis Verhoef; Thijs van Dalen Journal: Ann Surg Oncol Date: 2013-09-20 Impact factor: 5.344
Authors: Luis F Tapias; Mari Mino-Kenudson; Hang Lee; Cameron Wright; Henning A Gaissert; John C Wain; Douglas J Mathisen; Michael Lanuti Journal: Eur J Cardiothorac Surg Date: 2012-12-11 Impact factor: 4.191
Authors: Sepideh Gholami; Michael R Cassidy; Amanda Kirane; Deborah Kuk; Bhumika Zanchelli; Christina R Antonescu; Samuel Singer; Murray Brennan Journal: Ann Surg Oncol Date: 2017-10-16 Impact factor: 5.344
Authors: Mª A Vaz Salgado; M Soto; Mª E Reguero; G Muñoz; A Cabañero; I Gallego; S Resano; F Longo; A Madariaga; A Gomez; A Carrato Journal: Clin Transl Oncol Date: 2016-09-07 Impact factor: 3.405
Authors: Janani S Reisenauer; Wadad Mneimneh; Sarah Jenkins; Aaron S Mansfield; Marie Christine Aubry; Karen J Fritchie; Mark S Allen; Shanda H Blackmon; Stephen D Cassivi; Francis C Nichols; Dennis A Wigle; K Robert Shen; Jennifer M Boland Journal: J Thorac Oncol Date: 2018-06-20 Impact factor: 15.609
Authors: Elizabeth G Demicco; Min S Park; Dejka M Araujo; Patricia S Fox; Roland L Bassett; Raphael E Pollock; Alexander J Lazar; Wei-Lien Wang Journal: Mod Pathol Date: 2012-05-11 Impact factor: 7.842
Authors: S Salas; N Resseguier; J Y Blay; A Le Cesne; A Italiano; C Chevreau; P Rosset; N Isambert; P Soulie; D Cupissol; C Delcambre; J O Bay; P Dubray-Longeras; M Krengli; B De Bari; S Villa; J H A M Kaanders; S Torrente; D Pasquier; J O Thariat; L Myroslav; C V Sole; H F Dincbas; J Y Habboush; T Zilli; T Dragan; K Khan R; G Ugurluer; T Cena; F Duffaud; N Penel; F Bertucci; D Ranchere-Vince; P Terrier; S Bonvalot; N Macagno; C Lemoine; M Lae; J M Coindre; C Bouvier Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Giacomo G Baldi; Silvia Stacchiotti; Valentina Mauro; Angelo P Dei Tos; Alessandro Gronchi; Ugo Pastorino; Leonardo Duranti; Salvatore Provenzano; Andrea Marrari; Michela Libertini; Silvana Pilotti; Paolo G Casali Journal: Clin Sarcoma Res Date: 2013-04-03
Authors: Madelaine Hettler; Julia Kitz; Ali Seif Amir Hosseini; Manuel Guhlich; Babak Panahi; Jennifer Ernst; Lena-Christin Conradi; Michael Ghadimi; Philipp Ströbel; Jens Jakob Journal: Cancers (Basel) Date: 2022-09-05 Impact factor: 6.575